Why Teva Pharmaceutical Stock Is Sinking Today
Shares of Teva Pharmaceutical Industries ( TEVA -13.66%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.86%) and Nasdaq Composite ( ^IXIC -1.18%) lost 0.5% and 0.9%, respectively.
Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug price negotiations, and much more.
Why Teva Pharmaceutical Industries Limited’s (TEVA) Stock Is Down 13.89%
Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is right time to buy.
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name is Alex, and I will be coordinating the call today. [Operator instructions] And I hand it over to your host,
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,
Teva Pharmaceutical (TEVA) Gets a Buy from Barclays
Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.
Teva Pharmaceutical Posts Lower Revenue. Stock Slips.
Teva stock fell early Wednesday after the pharma giant reported adjusted earnings of 71 cents per share on $4.23 billion in fourth-quarter sales. Please watch the video at Investors.com - How To Buy Stocks: Cup-With-Handle Chart Pattern Analysts polled by FactSet expected Teva Pharmaceutical to earn 71 cents per share on $4.
Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.50%, Germany's DAX 40 gained 0.97% and France's CAC 40 fell 0.32%. Spain's IBEX 35 Index rose 1.09%, while London's FTSE 100 rose 0.28%.
Teva Pharmaceutical shares tumble as 2025 outlook disappoints
NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported fourth-quarter earnings that beat analyst estimates, but its shares fell sharply as the company's 2025 outlook came in below expectations.
Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...
FiercePharma12h
Teva, despite delivering in 2024, startles investors with subdued 2025 guidance
Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...
globes.co.il15h
Teva falls sharply on disappointing 2025 guidance
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by ...
Teva falls -12.5%
Teva (TEVA) is down -12.5%, or -$2.69 to $18.84.Invest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover their success rate ...
Teva Swings to 4Q Loss as Revenue Falls
Teva Pharmaceutical Industries swung to a fourth-quarter loss on lower revenue and an operating loss. Shares fell about 2.5% in premarket trading to $20.99.
Hosted on MSN11h
Teva Stock Dives 14%. Why Its CEO Says It's A Victim.
Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on ...
Teva price target lowered to $23 from $26 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Teva (TEVA) to $23 from $26 and keeps a Buy rating on the shares. For FY25, the ...
Teva on track for worst intraday loss in years on guidance miss
Teva Pharmaceutical (NYSE:TEVA) lost ~13%, posting what could be its biggest intraday decline since March 2020 after the generic drugmaker set its 2025 earnings outlook below consensus even as its Q4 ...